

DAFTAR PUSTAKA

- Arroyo, V., García-Martínez, R., & Salvatella, X. (2014). Human serum albumin, systemic inflammation, and cirrhosis. *Journal of Hepatology*. <https://doi.org/10.1016/j.jhep.2014.04.012>
- Bekelis, K., Bakhoun, S. F., Desai, A., Mackenzie, T. A., Goodney, P., & Labropoulos, N. (2013). A risk factor-based predictive model of outcomes in carotid endarterectomy: The national surgical quality improvement program 2005-2010. *Stroke*, *44*(4). <https://doi.org/10.1161/STROKEAHA.111.674358>
- Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: An update. *Hepatology*. <https://doi.org/10.1002/hep.24199>
- Cabrera, R. (2012). Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. *Hepatic Medicine: Evidence and Research*. <https://doi.org/10.2147/hmer.s16316>
- Chidambaranathan-Reghupaty, S., Fisher, P. B., & Sarkar, D. (2021). Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification. In *Advances in Cancer Research* (Vol. 149). <https://doi.org/10.1016/bs.acr.2020.10.001>
- D'Onofrio, M., Faccioli, N., Zamboni, G., Malagò, R., Caffarri, S., Fattovich, G., & Mucelli, R. P. (2008). Focal liver lesions in cirrhosis: value of contrast-enhanced ultrasonography compared with Doppler ultrasound and α -fetoprotein levels. *La radiologia medica*, *113*(7). <https://doi.org/10.1007/s11547-008-0316-z>
- Dahlan, M. (2016). *Besar Sampel dalam Penelitian Kedokteran dan Kesehatan. Sagung Seto*.
- Dănilă, M., & Sporea, I. (2014). Ultrasound screening for hepatocellular carcinoma in patients with advanced liver fibrosis. An overview. *Medical Ultrasonography*. <https://doi.org/10.11152/mu.201.3.2066.162.md1is2>
- Delli Pizzi, A., Mastrodicasa, D., Cianci, R., Serafini, F. L., Mincuzzi, E., Di Fabio, F., ... Caulo, M. (2021). Multimodality Imaging of Hepatocellular Carcinoma: From Diagnosis to Treatment Response Assessment in Everyday Clinical Practice. *Canadian Association of Radiologists Journal*, *72*(4). <https://doi.org/10.1177/0846537120923982>
- Fattovich, G., Giustina, G., Christensen, E., Pantalena, M., Zagni, I., Realdi, G., & Schalm, S. W. (2000). Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. *Gut*, *46*(3). <https://doi.org/10.1136/gut.46.3.420>

- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., ... Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*. <https://doi.org/10.1002/ijc.29210>
- Fitzmaurice, C., Akinyemiju, T. F., Al Lami, F. H., Alam, T., Alizadeh-Navaei, R., Allen, C., ... Naghavi, M. (2018). Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016 a systematic analysis for the global burden of disease study global burden of disease cancer collaboration. *JAMA Oncology*, 4(11). <https://doi.org/10.1001/jamaoncol.2018.2706>
- Ghanaati, H., Mohammadifard, M., & Mohammadifard, M. (2021). A review of applying transarterial chemoembolization (TACE) method for management of hepatocellular carcinoma. *Journal of Family Medicine and Primary Care*, 10(10). https://doi.org/10.4103/jfmpc.jfmpc_2347_20
- Gonsalves, C. F., & Brown, D. B. (2009). Chemoembolization of hepatic malignancy. *Abdominal Imaging*. <https://doi.org/10.1007/s00261-008-9446-y>
- Hanna, R. F., Miloussev, V. Z., Tang, A., Finklestone, L. A., Brejt, S. Z., Sandhu, R. S., ... Sirlin, C. B. (2016). Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. *Abdominal Radiology*, 41(1). <https://doi.org/10.1007/s00261-015-0592-8>
- Harding, J. J., Abu-Zeinah, G., Chou, J. F., Owen, D. H., Ly, M., Lowery, M. A., ... Abou-Alfa, G. K. (2018). Frequency, morbidity, and mortality of bone metastases in advanced hepatocellular carcinoma. *JNCCN Journal of the National Comprehensive Cancer Network*, 16(1). <https://doi.org/10.6004/jnccn.2017.7024>
- Hiraoka, A., Kumada, T., Michitaka, K., Toyoda, H., Tada, T., Ueki, H., ... Kawasaki, H. (2016). Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma. *Journal of Gastroenterology and Hepatology (Australia)*, 31(5). <https://doi.org/10.1111/jgh.13250>
- Ho, S. Y., Liu, P. H., Hsu, C. Y., Hsia, C. Y., Lee, Y. H., Lee, R. C., ... Huo, T. I. (2017). Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS ONE*, 12(7). <https://doi.org/10.1371/journal.pone.0180408>
- Hu, K., Yuan, J., Tang, B., Zhang, F., Lu, S., Chen, R., ... Yin, X. (2021). Albumin-bilirubin index and platelet-albumin-bilirubin index contribute to identifying survival benefit candidates in patients with hepatocellular carcinoma and Child-Pugh grade A undergoing transcatheter arterial chemoembolization with sorafenib treatment. *Annals of Translational Medicine*, 9(3).

<https://doi.org/10.21037/atm-20-3118>

- Ioannou, G. N., Green, P., Kerr, K. F., & Berry, K. (2019). Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. *Journal of Hepatology*, *71*(3). <https://doi.org/10.1016/j.jhep.2019.05.008>
- Ioannou, G. N., Splan, M. F., Weiss, N. S., McDonald, G. B., Beretta, L., & Lee, S. P. (2007). Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis. *Clinical Gastroenterology and Hepatology*, *5*(8). <https://doi.org/10.1016/j.cgh.2007.02.039>
- Johnson, P., Berhane, S., Kagebayashi, C., & Satomura, S. (2015). A nssessment of liver function in patients with hepatocellular carcinoma: A new evidence-based approach - The albi grade. *Journal of Clinical Oncology*, *33*(6).
- Kulik, L., & El-Serag, H. B. (2019). Epidemiology and Management of Hepatocellular Carcinoma. *Gastroenterology*, *156*(2). <https://doi.org/10.1053/j.gastro.2018.08.065>
- Lee, P. C., Chen, Y. T., Chao, Y., Huo, T. I., Li, C. P., Su, C. W., ... Huang, Y. H. (2018). Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma. *Liver International*, *38*(2). <https://doi.org/10.1111/liv.13527>
- Lee, S. W., Yen, C. L., Cheng, Y. C., Shun Yang, S., & Lee, T. Y. (2022). The radiological prognostic factors of transcatheter arterial chemoembolization to hepatocellular carcinoma. *Medicine (United States)*, *101*(41). <https://doi.org/10.1097/MD.00000000000030875>
- Lencioni, R., de Baere, T., Soulen, M. C., Rilling, W. S., & Geschwind, J. F. H. (2016). Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. *Hepatology*. <https://doi.org/10.1002/hep.28453>
- Levitt, D. G., & Levitt, M. D. (2016). Human serum albumin homeostasis: A new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements. *International Journal of General Medicine*. <https://doi.org/10.2147/IJGM.S102819>
- Lin, P. T., Teng, W., Jeng, W. J., Chen, W. T., Hsieh, Y. C., Huang, C. H., ... Sheen, I. S. (2022). Dynamic Change of Albumin-Bilirubin Score Is Good Predictive Parameter for Prognosis in Chronic Hepatitis C-hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization. *Diagnostics*, *12*(3). <https://doi.org/10.3390/diagnostics12030665>
- Liu, C., Wu, J., & Chang, Z. (2021). Trends and age-period-cohort effects on the prevalence, incidence and mortality of hepatocellular carcinoma from 2008 to 2017 in Tianjin, China. *International Journal of Environmental Research and Public Health*, *18*(11). <https://doi.org/10.3390/ijerph18116034>

- Lok, A. S., Seeff, L. B., Morgan, T. R., di Bisceglie, A. M., Sterling, R. K., Curto, T. M., ... Goodman, Z. D. (2009). Incidence of Hepatocellular Carcinoma and Associated Risk Factors in Hepatitis C-Related Advanced Liver Disease. *Gastroenterology*, *136*(1). <https://doi.org/10.1053/j.gastro.2008.09.014>
- Manitz, J., D'Angelo, S. P., Apolo, A. B., Eggleton, S. P., Bajars, M., Bohnsack, O., & Gulley, J. L. (2022). Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival. *Journal for ImmunoTherapy of Cancer*, *10*(2). <https://doi.org/10.1136/jitc-2021-003302>
- Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., ... Davila, J. A. (2016). Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated With Nonalcoholic Fatty Liver Disease. *Clinical Gastroenterology and Hepatology*, *14*(1). <https://doi.org/10.1016/j.cgh.2015.07.019>
- Miyayama, S. (2020). Treatment strategy of transarterial chemoembolization for hepatocellular carcinoma. *Applied Sciences (Switzerland)*. <https://doi.org/10.3390/app10207337>
- Miyayama, S., Yamashiro, M., Hashimoto, M., Hashimoto, N., Ikuno, M., Okumura, K., ... Matsui, O. (2014). Comparison of local control in transcatheter arterial chemoembolization of hepatocellular carcinoma ≥ 6 cm with or without intraprocedural monitoring of the embolized area using cone-beam computed tomography. *CardioVascular and Interventional Radiology*, *37*(2). <https://doi.org/10.1007/s00270-013-0667-2>
- Murakami, T., Hyodo, T., Tsurusaki, M., & Imai, Y. (2014). Clinical utility of imaging for evaluation of hepatocellular carcinoma. *Journal of Hepatocellular Carcinoma*. <https://doi.org/10.2147/jhc.s48602>
- Otto, G., Herber, S., Heise, M., Lohse, A. W., Mönch, C., Bittinger, F., ... Pitton, M. (2006). Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. *Liver Transplantation*, *12*(8). <https://doi.org/10.1002/lt.20837>
- Pinato, D. J., Yen, C., Bettinger, D., Ramaswami, R., Arizumi, T., Ward, C., ... Sharma, R. (2017). The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development. *Alimentary Pharmacology and Therapeutics*, *45*(5). <https://doi.org/10.1111/apt.13904>
- Schraml, C., Kaufmann, S., Rempp, H., Syha, R., Ketelsen, D., Notohamiprodjo, M., & Nikolaou, K. (2015). Imaging of HCC-current state of the art. *Diagnostics*, *5*(4). <https://doi.org/10.3390/diagnostics5040513>
- Schulze, K., Nault, J. C., & Villanueva, A. (2016). Genetic profiling of hepatocellular carcinoma using next-generation sequencing. *Journal of Hepatology*. <https://doi.org/10.1016/j.jhep.2016.05.035>

- Shao, Y. Y., Wang, S. Y., Lin, S. M., Chen, K. Y., Tseng, J. H., Ho, M. C., ... Hsieh, C. H. (2021). Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan. *Journal of the Formosan Medical Association*, 120(4). <https://doi.org/10.1016/j.jfma.2020.10.031>
- Sun, H. C., Zhang, W., Qin, L. X., Zhang, B. H., Ye, Q. H., Wang, L., ... Tang, Z. Y. (2007). Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. *Journal of Hepatology*, 47(5). <https://doi.org/10.1016/j.jhep.2007.06.019>
- Tang, A., Bashir, M. R., Corwin, M. T., Cruite, I., Dietrich, C. F., Do, R. K. G., ... Sirlin, C. B. (2018). Evidence supporting LI-RADS major features for CT- and MR imaging-based diagnosis of hepatocellular carcinoma: A systematic review. *Radiology*. <https://doi.org/10.1148/radiol.2017170554>
- Testino, G., Leone, S., & Borro, P. (2014). Alcohol and hepatocellular carcinoma: A review and a point of view. *World Journal of Gastroenterology*. <https://doi.org/10.3748/wjg.v20.i43.15943>
- Thiele, M., Glud, L. L., Fialla, A. D., Dahl, E. K., & Krag, A. (2014). Large variations in risk of hepatocellular carcinoma and mortality in treatment Naïve hepatitis B patients: Systematic review with meta-analyses. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0107177>
- Tseng, T. C., Liu, C. J., Yang, H. C., Su, T. H., Wang, C. C., Chen, C. L., ... Kao, J. H. (2012). High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. *Gastroenterology*, 142(5). <https://doi.org/10.1053/j.gastro.2012.02.007>
- Unsal, H., Vakicier, C., Marçais, C., Kew, M., Volkmann, M., Zentgraf, H., ... Ozturk, M. (1994). Genetic heterogeneity of hepatocellular carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, 91(2). <https://doi.org/10.1073/pnas.91.2.822>
- Waked, I., Berhane, S., Toyoda, H., Chan, S. L., Stern, N., Palmer, D., ... Johnson, P. J. (2017). Transarterial chemo-embolisation of hepatocellular carcinoma: Impact of liver function and vascular invasion. *British Journal of Cancer*, 116(4). <https://doi.org/10.1038/bjc.2016.423>
- Walter, S. R., Thein, H. H., Gidding, H. F., Amin, J., Law, M. G., George, J., & Dore, G. J. (2011). Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C. *Journal of Gastroenterology and Hepatology (Australia)*, 26(12). <https://doi.org/10.1111/j.1440-1746.2011.06785.x>
- Westermeier, R. (2016). Protein Sample Preparation. In *Electrophoresis in Practice*. <https://doi.org/10.1002/9783527695188.ch5>

- Yasui, K., Hashimoto, E., Komorizono, Y., Koike, K., Arai, S., Imai, Y., ... Okanoue, T. (2011). Characteristics of Patients With Nonalcoholic Steatohepatitis Who Develop Hepatocellular Carcinoma. *Clinical Gastroenterology and Hepatology*, 9(5). <https://doi.org/10.1016/j.cgh.2011.01.023>
- Young, M., & John, S. (2023). Hepatic Chemoembolization. Diambil dari https://www.ncbi.nlm.nih.gov/books/NBK507822/#_article-19369_s13_
- Yu, N. C., Chaudhari, V., Raman, S. S., Lassman, C., Tong, M. J., Busuttill, R. W., & Lu, D. S. K. (2011). CT and MRI Improve Detection of Hepatocellular Carcinoma, Compared With Ultrasound Alone, in Patients With Cirrhosis. *Clinical Gastroenterology and Hepatology*, 9(2). <https://doi.org/10.1016/j.cgh.2010.09.017>
- Zheng, R., Qu, C., Shang, S., & Zeng, H. (2018). Liver cancer incidence and mortality in China: Temporal trends and projections to 2030. *Chin J Cancer Res*, 30(6), 571–579. <https://doi.org/10.21147/j.issn.1000-9604.2018.06.01>